3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
17
Cisplatin
11
Carboplatin
9
Cyclophosphamide
8
fludarabine
6
Paclitaxel
6
Nivolumab
6
Bevacizumab
6
aldesleukin
5
Radiotherapy
5
toripalimab
4
tisotumab vedotin
4
fludarabine phosphate
4
Topotecan
4
Interleukin-2
4
Docetaxel
4
Brachytherapy
4
spartalizumab
3
Ipilimumab
3
Fulvestrant
3
ferumoxtran-10
2
enzalutamide
2
durvalumab
2
cemiplimab
2
bemarituzumab
2
balstilimab
2
Trastuzumab
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Cervical Neoplasms
×
AZD5305
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled